RECKITT BENCKISER LLC

ACTIVE

4 Mill Ridge Ln, 新泽西州摩里斯县, New Jersey, United Stateswww.lysol.comSubsidiaryEstablished: 1889-01-01

Part of RECKITT BENCKISER GROUP PLC

Clinical Trials

0 active

Approvals

Total approvals

Agencies

Regulatory bodies

Founded

1889

Overview

Trial Phase Distribution

Phase

Trials

Phase 1

26.7%

Phase 3

26.7%

Not Applicable

13.3%

Phase 2

13.3%

Phase 4

13.3%

Unknown

6.7%

Trial Status Distribution

Completed

100.0%

Clinical Trials

Trials sponsored by this organization (15)

Study to Evaluate the Safety and Tolerability of Mucinex™(Guaifenesin) 600 mg Extended-Release Bi-Layer Tablets in the Treatment of Otherwise Healthy Patients With Symptoms of Cough, Thickened Mucus and Chest Congestion

Phase 4

Completed

interventional

Jan 2015552 participants

MucinexTM (Guaifenesin) 600 mg Extended-Release Bi-Layer Tablets Safety and Tolerability Post Marketing Surveillance Study

Unknown

Completed

observational

Jan 2015650 participants

Placebo-Controlled Onset-of-Action Study of Flurbiprofen Utilizing the Double-Stopwatch Method

Phase 3

Completed

interventional

Sep 2013122 participants

Study to Evaluate the Pharmacokinetics of Mucinex® 1200 mg Extended-Release Tablet

Phase 1

Completed

interventional

Oct 201124 participants

Safety and Efficacy of Mucinex and IR Guaifenesin the Treatment of Symptoms of Acute Upper Respiratory Tract Infections

Phase 2

Completed

interventional

Sep 20112,810 participants

Page 1 of 2

Approvals

Approvals by Agency

FDA

Food and Drug Administration

Approvals

Recent Approvals

Mucinex Fast-Max DM Max Honey and Berry Flavor

Biofreeze Ultraflex Plus

FDA

2026-06-02

Mucinex Childrens Mighty Chews Cough

FDA

2026-05-31

Mucinex Childrens Mighty Chews Cough Nighttime

News

No news articles found

Back to Organizations

RECKITT BENCKISER LLC

Overview

Trial Phase Distribution

Trial Status Distribution

Clinical Trials

Trials sponsored by this organization (15)

Study to Evaluate the Safety and Tolerability of Mucinex™(Guaifenesin) 600 mg Extended-Release Bi-Layer Tablets in the Treatment of Otherwise Healthy Patients With Symptoms of Cough, Thickened Mucus and Chest Congestion

MucinexTM (Guaifenesin) 600 mg Extended-Release Bi-Layer Tablets Safety and Tolerability Post Marketing Surveillance Study

Placebo-Controlled Onset-of-Action Study of Flurbiprofen Utilizing the Double-Stopwatch Method

Mucinex® ER 600 mg Bi-Layer Tablet Fed and Fasted

Evaluation of Tolerance and Acceptability of a Coated Condom

Safety & Performance Study of Verruca Treatment Device

Study to Evaluate the Pharmacokinetics of Mucinex® 1200 mg Extended-Release Tablet

Safety and Efficacy of Mucinex and IR Guaifenesin the Treatment of Symptoms of Acute Upper Respiratory Tract Infections

Approvals

Approvals by Agency

Recent Approvals

News